Hunstman Cancer Institute
Salt Lake City, Utah 84112
We've found
1 trials
at this facility
Non-Hodgkin's Lymphoma Clinical Trial
Updated: 12/31/1969
A Dose Escalation Study of RO7082859 as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
